Weal and woe of interleukin-18 in the T cell therapy of cancer.

IF 10.3 1区医学 Q1 IMMUNOLOGY

Journal for Immunotherapy of Cancer Pub Date : 2025-01-14 DOI:10.1136/jitc-2024-010545

Christoph Kessel, Claudia Rossig, Hinrich Abken

引用次数: 0

Abstract

Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a double-edged sword in CAR T cell therapies.

查看原文本刊更多论文

白细胞介素-18在肿瘤T细胞治疗中的利弊。

嵌合抗原受体（CAR） T细胞治疗实体癌仍低于预期；通过IL-18添加细胞因子帮助在首次临床试验中显示出显著的疗效。由于IL-18也是高炎症条件的强大驱动因素，我们讨论了在CAR - T细胞治疗中释放IL-18在多大程度上是一把双刃剑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal for Immunotherapy of Cancer Biochemistry, Genetics and Molecular Biology-Molecular Medicine

CiteScore

17.70

自引率

4.60%

发文量

522

审稿时长

18 weeks

期刊介绍： The Journal for ImmunoTherapy of Cancer (JITC) is a peer-reviewed publication that promotes scientific exchange and deepens knowledge in the constantly evolving fields of tumor immunology and cancer immunotherapy. With an open access format, JITC encourages widespread access to its findings. The journal covers a wide range of topics, spanning from basic science to translational and clinical research. Key areas of interest include tumor-host interactions, the intricate tumor microenvironment, animal models, the identification of predictive and prognostic immune biomarkers, groundbreaking pharmaceutical and cellular therapies, innovative vaccines, combination immune-based treatments, and the study of immune-related toxicity.